臨床研究等提出・公開システム

Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (LOMCAD)

LOMCAD Trial (LOMCAD)

Ohara Tomoyuki

University Hospital Kyoto Prefectural University of Medcine

465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566 Japan

lomcad@koto.kpu-m.ac.jp

Mizuta Ikuko

Graduate School of Medical Science, Kyoto Prefectural University of Medicine

465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566 Japan

+81-75-251-5793

lomcad@koto.kpu-m.ac.jp

Complete

Aug. 09, 2022

Interventional

single arm study

open(masking not used)

historical control

single assignment

treatment purpose

Patients meeting all of the following criteria will be included
1) Patients diagnosed with CADASIL by genetic testing
2) Patients with "symptomatic cerebral infarction, transient ischemic attack, or asymptomatic MRI diffusion-weighted imaging (DWI) detection of acute ischemic lesions" within 6 months prior to obtaining consent, and once or more within 2 years prior to the most recent "symptomatic cerebral infarction, transient ischemic attack, or asymptomatic head MRI DWI detection of acute ischemic foci" .
3) Patients who are between 20 and 70 years of age at the time of consent
4) Patients who have obtained written consent from the patient or a surrogate to participate in the clinical trial.

Patients who fall into any of the following categories will not be included in this study
1) Patients who have taken lomerizine hydrochloride for more than 1 month continuously within 1 year prior to enrollment
2) Patients with a history of hypersensitivity to lomerizine hydrochloride
3) Patients with a history of symptomatic intracranial hemorrhage
4) Patients who are unable to discontinue acetazolamide medication
5) Patients on concomitant antiplatelet and anticoagulant medications or taking two or more antiplatelet medications at the time of enrollment
6) Patients with severe hepatic dysfunction at the time of enrollment
7) Women who wish to become pregnant during the study period, are pregnant, may become pregnant, or are breastfeeding at the time of consent
8) Patients with a modified Rankin Scale (mRS) of 4 or higher at the time of enrollment
9) Patients who are unable to undergo MRI examinations (claustrophobia, metal in the body, etc.)
10) Patients who cannot have a baseline MRI examination at the study site within 42 days prior to enrollment
11) Patients who are participating in another clinical trial at the time of consent
12) Other patients who are deemed by the investigator to be inappropriate to participate in the clinical trial.

Both

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)

Lomerizine hydrochloride (MIGSYS tablets 5 mg, 1 tablet twice daily) will be administered continuously for 24 months as the study drug.

CADASIL

lomerizine hydrochloride

D046589

C052424

Symptomatic cerebral ischemic events during the 24 months following start of study treatment

1) Number of symptomatic cerebral ischemic events during the 24 months following start of study treatment
2) Incidence of all cerebral ischemic events during the 24 months following start of study treatment
3) Changes in modified Rankin Scale (mRS)

+81-75-251-5337

none